6-[1-(2,6-Difluorophenyl)ethyl]pyrimidinones antagonize cell proliferation and induce cell differentiation by inhibiting (a nontelomeric) endogenous reverse transcriptase

Journal of Medicinal Chemistry

Volumn 48, Issue 22, 2005, Pages 6776-6778

  Bartolini, Sara ^a   Mai, Antonello ^b   Artico, Marino ^b   Paesano, Nicola ^c   Rotili, Dante ^b   Spadafora, Corrado ^a   Sbardella, Gianluca ^c  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 [1 (2,6 DIFLUOROPHENYL)ETHYL]PYRIMIDINONE DERIVATIVE; EFAVIRENZ; MC 1047; MC 1220; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG STRUCTURE; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 27444434731     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0507330     Document Type: Article

References (23)

1. Schramke, V.; Allshire, R. Hairpin. RNAs and retrotransposon LTRs effect RNAi and chromatin-based gene silencing. Science 2003, 301, 1069-1074.
2. Sciamanna, I.; Landriscina, M.; Pittoggi, C.; Quirino, M.; Mearelli, C.; Beraldi, R.; Mattei, E.; Serafino, A.; Cassano, A.; Sinibaldi-Vallebona, P.; Garaci, E.; Barone, C.; Spadafora, C. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene 2005, 24, 3923-3931 and references therein reported.
3. Deininger, P. L.; Moran, J. V.; Batzer, M. A.; Kazazian, H. H. Mobile elements and mammalian genome evolution. Curr. Opin. Genet. Dev. 2003, 13, 651-658.
4. Pyra, H.; Boni, J.; Schupbach, J. Ultrasensitive retrovirus detection by a reverse transcriptase assay based on product enhancement. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 1544-1548
5. Mangiacasale, R.; Pittoggi, C.; Sciamanna, I.; Careddu, A.; Mattei, E.; Lorenzini, R.; Travaglini, L.; Landriscina, M.; Barone, C.; Nervi, C.; Lavia, P.; Spadafora, C. Exposure of normal and transformed cells to nevirapine, a Reverse Transcriptase inhibitor, reduces cell growth and promotes differentiation. Oncogene 2003, 22, 2750-2761.
6. Pittoggi, C.; Sciamanna, I.; Mattei, E.; Beraldi, R.; Lobascio, A. M.; Mai, A.; Quaglia, M. G.; Lorenzini, R.; Spadafora, C. Role of endogenous reverse transcriptase in murine early embryo development. Mol. Reprod. Dev. 2003, 66, 225-236.
7. Artico, M.; Massa, S.; Mai, A.; Marongiu, M. E.; Piras, G.; Tramontano, E.; La Colla, P. 3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs): a new class of specific inhibitors of human immunodeficiency virus type 1. Antiviral Chem. Chemother. 1993, 4, 361-368.
8. Massa, S., Mai, A.; Artico, M.; Sbardella, G.; Tramontano, E.; Loi, A. G.; Scano, P.; La Colla, P. Synthesis and antiviral activity of new 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), specific inhibitors of human immunodeficiency virus Type-1. Antiviral Chem. Chemother. 1995, 6, 1-8.
9. Mai, A., Artico, M.; Sbardella, G.; Massa, S.; Loi, A. G.; Tramontano, E.; Scano, P.; La Colla, P. Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines. J. Med. Chem. 1995, 38, 3258-3263.
10. Mai, A.; Artico, M.; Sbardella, G.; Quartarone, S.; Massa, S.; Loi, A. G.; De Montis, A.; Scintu, F.; Putzolu, M.; La Colla, P. Dihydro(alkylthio) (naphthylmethyl) oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series. J. Med. Chem. 1997, 40, 1447-1454.
11. Mai, A.; Artico, M.; Sbardella, G.; Massa, S.; Novellino, E.; Greco, G.; Loi A. G.; Tramontano, E.; Marongiu, M. E.; La Colla, P. 5-Alkyl-2-(alkylthio)- 6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4 (3H)-ones: novel potent and selective dihydro-alkoxybenzyl-oxopyrimidine derivatives. J. Med. Chem. 1999, 42, 619-627.
12. Artico, M.; Mai, A.; Sbardella, G.; Massa, S.; Marceddu, T.; Vargiu, L.; Marongiu, M. E.; La Colla, P. Does the 2-methylthiomethyl substituent really confer high anti-HIV-1 activity to S-DABOs? Med. Chem. Res. 2000, 10, 30-39.
13. Mai, A.; Sbardella, G.; Artico, M.; Ragno, R.; Massa, S.; Novellino, E.; Greco, G.; Lavecchia, A.; Musiu, C.; La Colla, M.; Murgioni, C.; La Colla, P.; Loddo, R. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl) alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Chem. 2001, 44, 2544-2554.
14. Sbardella, G.; Mai, A.; Artico, M.; Chimenti, P.; Massa, S.; Loddo, R.; Marongiu, M. E.; La Colla, P.; Pani A. Structure-activity relationship studies on new DABOs: effect of substitutions at pyrimidine C-5 and C-6 positions on anti-HIV-1 activity. Antiviral Chem. Chemother. 2001, 12, 37-50.
15. Pani, A.; Musiu, C.; Loi, A. G.; Mai, A.; Loddo, R.; La Colla, P.; Marongiu, M. E. DABOs as candidates to prevent mucosal HIV transmission Antiviral Chem. Chemother. 2001, (Suppl. 1), 51-59.
16. Ragno, R.; Mai, A.; Sbardella, G.; Artico, M.; Massa, S.; Musiu, C.; Mura, M.; Marceddu, T.; Cadeddu, A.; La Colla, P. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6- difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4-(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. J. Med. Chem. 2004, 47, 928-934.
17. Mai, A.; Artico, M.; Ragno, R.; Sbardella, G.; Massa, S.; Musiu, C.; Mura, M.; Marturana, F.; Cadeddu, A.; Maga, G.; La Colla, P. 5-Alkyl-2-alkyl amino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new series of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family. Bioorg. Med. Chem. 2005, 13, 2065-2077.
18. 2-DABOs endowed with the best selectivity index (cytotoxic concentration/effective concentration ratio). Compounds 1 and 2 meet the requirements (references 13 and 15).
19. As a first approach we decided to test only the two racemic forms. Biological assays for both the enantiomers of compound 1 as well as chiral resolution of racemic 2 are in progress.
20. Maximum testable concentration for efavirenz in this condition was 15 μM.
21. A very comprehensive review of experimental methods in cell death analysis can be found in Robinson, J. P. The Purdue Cytometry CD-ROM; Purdue University Cytometry Laboratories: West Lafayette, IN, 2000; Volume 5. ISBN 1-890473-05-7, http://flowcyt.cyto.purdue.edu/flowcyt/cdseries.htm.
22. Damm, K.; Hemmann, U.; Garin-Chesa, P.; Hauel, N.; Kauffmann, I.; Priepke, H.; Niestroj, C.; Daiber, C.; Enenkel, B.; Guilliard, B.; Lauritsch, I.; Muller, E.; Pascolo, E.; Sauter, G.; Pantic, M.; Martens, U. M.; Wenz, C.; Lingner, J.; Kraut, N.; Rettig, W. J.; Schnapp, A. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 2001, 20, 6958-68.
23. Blasco, M. A.; Lee, H. W.; Hande, M. P.; Samper, E.; Lansdorp, P. M.; DePinho, R. A.; Greider, C. W. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997, 91, 25-34.